標(biāo)題：Research Grade Tezepelumab特折魯單抗,AntibodySystem Laboratories

鏈接：https://www.antibodysystem.com/product/89.html

名稱：Research Grade Tezepelumab特折魯單抗

別名：Tezepelumab特折魯單抗，AMG157, AMG-157, MEDI-9929, MEDI9929, anti-TSLP-Receptor (TSLP-R, Crl2)

CAS: 1572943-04-4

貨號(hào)：DHJ36101

適用物種：Human

寄主物種：Homo sapiens

形式：Liquid

純度：>95%

克隆性：Monoclonal

同種型：IgG2-lambda

應(yīng)用：Research Grade Biosimilar

UniProt：Q969D9

用途范圍：僅用于科研

靶點(diǎn)：TSLP, Thymic stromal lymphopoietin

儲(chǔ)存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購(gòu)買聯(lián)系方式：027-65279366 /18162686757

郵箱：biolab-reagents@atagenix.com

QQ：2663991332

參考文獻(xiàn)：

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. PMID: 33979488

Tezepelumab: First Approval. PMID: 35184265

Tezepelumab in Adults with Uncontrolled Asthma. PMID: 31034183

Tezepelumab. PMID: 36810033

Tezepelumab in patients with allergic and eosinophilic asthma. PMID: 38146651

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. PMID: 36702146

Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. PMID: 36538979

Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma. PMID: 37724378

Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. PMID: 37015033

Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies. PMID: 37772607

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. PMID: 34913186

Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma. PMID: 36470789

Tezepelumab for asthma. PMID: 36651067

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. PMID: 33050934

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. PMID: 35364018

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. PMID: 34256031

Tezepelumab-ekko. PMID: 35108361

Positioning of Tezepelumab in Severe Asthma. PMID: 37812191

Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study. PMID: 36507576

Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis. PMID: 36425526

Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis. PMID: 35269440

Tezepelumab in the Treatment of Uncontrolled Severe Asthma. PMID: 35535458

Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR). PMID: 37619779

Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial. PMID: 36223848

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR. PMID: 37692126

Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. PMID: 31549891

The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). PMID: 34049943

Effects of Tezepelumab on Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: Systematic Review and Meta-Analysis. PMID: 37191902

DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. PMID: 33087119

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. PMID: 33050928

Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. PMID: 35570578

Is tezepelumab more than just an anti-eosinophil drug? PMID: 34972684

Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study. PMID: 37263380

The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials. PMID: 36601189

Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma. PMID: 37496871

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma. PMID: 33922072

Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. PMID: 30550828

Dupilumab and tezepelumab in severe refractory asthma: new opportunities. PMID: 35655942

[Tezepelumab: a new option for the treatment of severe asthma]. PMID: 37995367

Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. PMID: 38524099